Louise Rodino-Klapac - 16 Nov 2021 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role: Chief Scientific Officer
Signature: /s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac
Issuer symbol: SRPT
Transactions as of: 16 Nov 2021
Net transactions value: $0
Form type: 4
Filing time: 17 Nov 2021, 19:03:46 UTC
Next filing: 29 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRPT	Common Stock	Award	$0	+40,000	+183%	$0.000000	61,898	16 Nov 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
F2	The amount of securities directly owned by the reporting person includes 118 shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan on August 31, 2021.

Content

The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

The amount of securities directly owned by the reporting person includes 118 shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan on August 31, 2021.